Roche's Alecensa bests Pfizer's Xalkori in lung cancer trial

CHICAGO (Reuters) - Roche Holding AG's Alecensa halted the spread of lung cancer for a median of 15 months longer than treatment with rival Pfizer Inc's Xalkori with fewer side effects, according to trial results presented on Monday.